ETON Insider Trading Activity and SEC Form 4 Filings
ETON insider trading summary
Over the past 12 months, insiders at Eton Pharmaceuticals, Inc. (ETON) reported 29 sales worth $29.4M by 5 insiders and no open-market purchases on SEC Form 4. Net insider selling was $29.4M.
Latest ETON insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Oct 6, 2026 | David Krempa | Chief Business Officer | Sell | $229K (4,166 @ $55.07) |
| Aug 28, 2026 | Paul V Maier | Director | Sell | $812K (13,485 @ $60.21) |
| Aug 28, 2026 | Paul V Maier | Director | Sell | $2.1M (36,387 @ $58.64) |
| Aug 28, 2026 | Paul V Maier | Director | Sell | $8K (128 @ $61.77) |
| Aug 28, 2026 | Paul V Maier | Director | Sell | $812K (13,485 @ $60.21) |
| Aug 28, 2026 | Paul V Maier | Director | Sell | $2.1M (36,387 @ $58.64) |
| Aug 28, 2026 | Paul V Maier | Director | Sell | $8K (128 @ $61.77) |
| Aug 24, 2026 | David Krempa | Chief Business Officer | Sell | $1.6M (25,000 @ $65.07) |
| Aug 20, 2026 | Sean Brynjelsen | President & CEO | Sell | $2.2M (36,373 @ $61.11) |
| Aug 20, 2026 | Sean Brynjelsen | President & CEO | Sell | $456K (7,342 @ $62.12) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.